Abstract
Preservation of fertility is a key determinant of long-term quality of life of adolescents and young adults treated for curable forms of cancer. The risk of developing primary or secondary infertility after completion of their treatment is variable and difficult to predict. Moreover, evaluation of the extent and reversibility of gonadotoxicity of cancer therapies is currently imperfect, especially in young women.
The most established method of preserving fertility is sperm banking in men and embryo cryopreservation in young women who have a partner. However, many alternative, though still experimental, options are in development that can already be proposed to young patients in well-defined conditions.
Despite the progress and refinement of fertility preservation techniques and the increase in educational resources, an information gap between patients and healthcare teams still persists. As the new field of oncofertility goes forward, concerted efforts must be made to improve communication of information to patients by integrating these features in pretreatment discussion and in definition of therapeutic strategies.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Knopman JM, Papadopoulos EB, Grifo JA, Fino ME, Noyes N. Surviving childhood and reproductive-age malignancy: effects on fertility and future parenthood. Lancet Oncol. 2010;11(5):490–8.
Levine J, Canada A, Stern CJ. Fertility preservation in adolescents and young adults with cancer. J Clin Oncol. 2010;28(32):4831–41.
Sonmezer M, Oktay K. Fertility preservation in young women undergoing breast cancer therapy. Oncologist. 2006;11(5):422–34.
Jeruss JS, Woodruff TK. Preservation of fertility in patients with cancer. N Engl J Med. 2009;360(9):902–11.
Peate M, Meiser B, Friedlander M, Zorbas H, Rovelli S, Sansom-Daly U, et al. It’s now or never: fertility-related knowledge, decision-making preferences, and treatment intentions in young women with breast cancer – an Australian fertility decision aid collaborative group study. J Clin Oncol. 2011;29(13):1670–7.
Feldschuh J, Brassel J, Durso N, Levine A. Successful sperm storage for 28 years. Fertil Steril. 2005;84(4):1017.
Sukumvanich P, Case LD, Van Zee K, Singletary SE, Paskett ED, Petrek JA, et al. Incidence and time course of bleeding after long-term amenorrhea after breast cancer treatment: a prospective study. Cancer. 2010;116(13):3102–11.
Reh A, Oktem O, Oktay K. Impact of breast cancer chemotherapy on ovarian reserve: a prospective observational analysis by menstrual history and ovarian reserve markers. Fertil Steril. 2008;90(5):1635–9.
Sönmezer M, Türkçüoğlu I, Coşkun U, Oktay K. Random-start controlled ovarian hyperstimulation for emergency fertility preservation in letrozole cycles. Fertil Steril. 2011;95(6):2125.e9–11.
Oktay K, Buyuk E, Libertella N, Akar M, Rosenwaks Z. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol. 2005;23(19):4347–53.
Azim AA, Costantini-Ferrando M, Oktay K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. J Clin Oncol. 2008;26(16):2630–5.
Sonmezer M, Oktay K. Orthotopic and heterotopic ovarian tissue transplantation. Best Pract Res Clin Obstet Gynaecol. 2010;24(1):113–26.
Donnez J, Dolmans MM, Demylle D, Jadoul P, Pirard C, Squifflet J, et al. Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet. 2004;364(9443):1405–10. Erratum in: Lancet. 2004;364(9450):2020.
Dolmans MM, Marinescu C, Saussoy P, Van Langendonckt A, Amorim C, Donnez J. Reimplantation of cryopreserved ovarian tissue from patients with acute lymphoblastic leukemia is potentially unsafe. Blood. 2010;116(16):2908–14.
Rosendahl M, Timmermans Wielenga V, Nedergaard L, Kristensen SG, Ernst E, et al. Cryopreservation of ovarian tissue for fertility preservation: no evidence of malignant cell contamination in Âovarian tissue from patients with breast cancer. Fertil Steril. 2011;95(6):2158–61.
Gerber B, von Minckwitz G, Stehle H, Reimer T, Felberbaum R, Maass N, et al. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J Clin Oncol. 2011;29(17):2334–41.
Del Mastro L, Boni L, Michelotti A, Gamucci T, Olmeo N, Gori S, et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA. 2011;306(3):269–76.
Bedaiwy MA, Abou-Setta AM, Desai N, Hurd W, Starks D, El-Nashar SA, et al. Gonadotropin-releasing hormone analog cotreatment for preservation of ovarian function during gonadotoxic chemotherapy: a systematic review and meta-analysis. Fertil Steril. 2011;95(3):906–14.e1–4.
Behringer K, Wildt L, Mueller H, Mattle V, Ganitis P, van den Hoonaard B, et al. No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group. Ann Oncol. 2010;21(10):2052–60.
Lee SJ, Schover LR, Partridge AH, Patrizio P, Hamish Wallace W, Hagerty K, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol. 2006;24(18):2917–31.
Quinn GP, Vadaparampil ST, Lee JH, Jacobsen PB, Bepler G, Lancaster J, et al. Physician referral for fertility preservation in oncology patients: a national study of practice behaviors. J Clin Oncol. 2009;27(35):5952–7.
Schover LR, Brey K, Lichtin A, Lipshultz LI, Jeha S. Oncologists’ attitudes and practices regarding banking sperm before cancer treatment. J Clin Oncol. 2002;20(7):1890–7.
Quinn GP, Vadaparampil ST, Malo T, Reinecke J, Bower B, Albrecht T, et al. Oncologists’ use of patient educational materials about cancer and fertility preservation. Psychooncology. 2011. doi:10.1002/pon.2022.
Letourneau JM, Ebbel EE, Katz PP, Katz A, Ai WZ, Chien AJ, et al. Pretreatment fertility counseling and fertility preservation improve quality of life in reproductive age women with cancer. Cancer. 2011. doi:10.1002/cncr.26459.
Azim Jr HA, Santoro L, Pavlidis N, Gelber S, Kroman N, Azim H, et al. Safety of pregnancy following breast cancer diagnosis: a meta-analysis of 14 studies. Eur J Cancer. 2011;47(1):74–83.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag London
About this chapter
Cite this chapter
Caroline, D., Ries, F. (2013). Preservation of Fertility in the Cancer Patient. In: Dicato, M. (eds) Side Effects of Medical Cancer Therapy. Springer, London. https://doi.org/10.1007/978-0-85729-787-7_14
Download citation
DOI: https://doi.org/10.1007/978-0-85729-787-7_14
Published:
Publisher Name: Springer, London
Print ISBN: 978-0-85729-786-0
Online ISBN: 978-0-85729-787-7
eBook Packages: MedicineMedicine (R0)